ICER publishes evidence report on fezolinetant for vasomotor symptoms associated with menopause

1 December 2022 - Evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for ...

Read more →

PBAC Public Summary Document (November 2022)

18 November 2022 - The Public Summary Documents for the Review of the base-case discount rate in the PBAC Guidelines from ...

Read more →

Public Summary Documents – September 2022 PBAC meeting

11 November 2022 - The Public Summary Document for tixagevimab and cilgavimab (Evusheld) from the September 2022 PBAC intracycle meeting is ...

Read more →

Public Summary Documents (first time decisions not to recommend and deferrals) - July 2022 PBAC meeting

11 November 2022 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the July 2022 PBAC ...

Read more →

Outcome statement - September 2022 DUSC meeting

3 November 2022 - The outcome statement from the September 2022 DUSC meeting is now available. ...

Read more →

Public Summary Documents – July 2022 PBAC meeting

28 October 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2022 PBAC ...

Read more →

DUSC utilisation analysis public release documents (October 2022)

25 October 2022 - The utilisation analysis public release documents from the June 2022 DUSC meeting are now available. ...

Read more →

ICER publishes final evidence report and policy recommendations on treatments for obesity management

20 October 2022 - Independent appraisal committee voted that evidence is adequate to demonstrate that semaglutide provides a net health benefit ...

Read more →

ICER releases draft evidence report on treatments for multiple sclerosis

17 October 2022 - Public comment period now open until 11 November 2022; requests to make oral comment during public ...

Read more →

HARmonized protocol template to enhance reproducibility of hypothesis evaluating real world evidence studies on treatment effects: a good practices report of a joint ISPE/ISPOR Task Force

12 October 2022 - Ambiguity in communication of key study parameters limits the utility of real-world evidence studies in health care ...

Read more →

ICER releases draft evidence report on treatment for vasomotor symptoms associated with menopause

11 October 2022 - Registration now open for October 19 “Early Insights” webinar. ...

Read more →

Independent review of paracetamol overdose

14 September 2022 - The TGA has published an independent expert report examining the incidence of serious injury and death ...

Read more →

ICER releases draft evidence report on gene therapies for haemophilia A and B

13 September 2022 - Registration now open for 20 September “Early Insights” webinar. ...

Read more →

ICER publishes final evidence report and policy recommendations on treatments for amyotrophic lateral sclerosis

13 September 2022 - Majority of independent appraisal committee voted that evidence is adequate to demonstrate that both AMX0035 and oral ...

Read more →

PBAC Public Summary Documents (first time rejections and deferrals) - May 2022 meeting

9 September 2022 - The Public Summary Documents (first time rejections and deferrals) from the May 2022 PBAC meeting are now ...

Read more →